Login Register Cart 0
Generic placeholder image

Applied Drug Research, Clinical Trials and Regulatory Affairs

Editor-in-Chief

ISSN (Print): 2667-3371
ISSN (Online): 2667-338X

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Review of Modified Oral Solid Drug Delivery System and Recent Active Patents

Author(s): Sachin S. Gaikwad*, Shrikant K. Ainor, Narayan B. Lande and Kishor S. Salunkhe

Volume 9, Issue 1, 2022

Published on: 13 December, 2022

Article ID: e081122210743 Pages: 10

DOI: 10.2174/2667337109666221108141059

Price: $65

Abstract

Background: A tablet is a solid dosage form containing Active Pharmaceutical Ingredients (API) and various excipients. Different procedures, such as direct compression of powder mixtures, and dry and wet granulation technologies, are used to create distinct types of tablets. Tablet development is aided by technological advancements in the form of modified-release tablets.

Objective: The modified release dosage form can be manufactured to obtain a specific pharmaceutical profile, the specific site of action and reduce the number of dose administrations using a variety of coating technologies. For modified released drug delivery, various sorts of patents are explored. The review's primary goal is to provide information on modified release formulations, formulation methodologies, current active patents based on modified release, and tablet coating technologies.

Conclusion: The tablet is a common and convenient pharmaceutical dosage form. Recently, modified release drug administration has largely supplanted traditional tablet drug delivery technologies. The chrono pharmaceutical drug delivery can also involve modified drug delivery. Modified release tablets are used to boost the therapeutic impact of medicine by targeting the location of action on the illness condition. Modified-release tablets are very handy, easy to create, cost-effective, and do not require high-cost equipment, and they are gaining in popularity these days. Patents for modified-release tablet dosage formulations that are currently active were also discussed.

Graphical Abstract

[1]
Hassan SD, Santanu R, Verma P, Bhandari V. A review on recent advances of enteric coating. IOSR J Pharm 2012; 2(6): 11.
[http://dx.doi.org/10.9790/3013-2610511]
[2]
Sackey J, Olowosulu AK, Abdulsamad A, Gwary S. Design and evaluation of time-dependent delayed-release diclofenac sodium tablets for chronopharmaceutical drug delivery. British J Pharm 2019; 4(2): 3-1.
[3]
Bejugam NK, Mutyam SK, Shankar GN. Tablet formulation of an active pharmaceutical ingredient with a sticking and filming problem: direct compression and dry granulation evaluations. Drug-Defined Pharm 2015; 41(2): 333-41.
[http://dx.doi.org/10.3109/03639045.2013.859266]
[4]
Ubhe TS, Gedam P. A brief overview on tablet and its types. J Adv Pharmacology 2020; 1(1): 21-31.
[5]
Dutta S, Sengupta M, Rao LB. Modified release drug and dosage form. J Pharm Res 2009; 2(11): 1728-9.
[6]
Gazzaniga A, Iamartino P, Maffione G, Sangalli ME. Oral delayed-release system for colonic specific delivery. Int J Pharm 1994; 108(1): 77-83.
[http://dx.doi.org/10.1016/0378-5173(94)90418-9]
[7]
Varum FJO, Merchant HA, Basit AW. Oral modified-release formulations in motion: The relationship between gastrointestinal transit and drug absorption. Int J Pharm 2010; 395(1-2): 26-36.
[http://dx.doi.org/10.1016/j.ijpharm.2010.04.046] [PMID: 20546855]
[8]
Gaikwad SS, Avhad RD, Kalkotwar RS. Formulation, development and in vitro characterization of modified release tablets of capecitabine. Drug Dev Ind Pharm 2020; 46(1): 20-30.
[http://dx.doi.org/10.1080/03639045.2019.1698595] [PMID: 31778085]
[9]
Bhowmik D, Duraivel SANR, Kumar KS. The tablet manufacturing process and defects of tablets. Elixir Pharmacy 2014; 70: 24368-74.
[10]
Nyol S, Gupta MM. Immediate drug release dosage form: A review. J Drug Deliv Ther 2013; 3(2): 155-61.
[http://dx.doi.org/10.22270/jddt.v3i2.457]
[11]
Kristensen J, Schaefer T, Kleinebudde P. Development of fastdisintegrating pellets in a rotary processor. Drug-defined pharm 2002; 28(10): 1201-.
[http://dx.doi.org/ 10.1081/DDC-120015353]
[12]
Arndt OR, Baggio R, Adam AK, Harting J, Franceschinis E, Kleinebudde P. Impact of different dry and wet granulation techniques on granule and tablet properties: A comparative study. J Pharm Sci 2018; 107(12): 3143-52.
[http://dx.doi.org/10.1016/j.xphs.2018.09.006] [PMID: 30244008]
[13]
Herting MG, Kleinebudde P. Roll compaction/dry granulation: Effect of raw material particle size on granule and tablet properties. Int J Pharm 2007; 338(1-2): 110-8.
[http://dx.doi.org/10.1016/j.ijpharm.2007.01.035] [PMID: 17324537]
[14]
Sood R, Rathore MS, Sharma A, Thakur R, Chaudhari J, Soni V. Immediate release antihypertensive valsartan oral tablet: A Review. J Sci Res Pharm 2012; 1(2): 20-6.
[15]
Alton MG, Taylor ME. Pharmaceutics-the design and manufacture of medicines. 4th ed. Leicester, UK Elsevier publication. 2013.
[16]
Tran PHL, Tran TTD. Dosage form designs for the controlled drug release of solid dispersions. Int J Pharm 2020; 581: 119274.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119274] [PMID: 32234566]
[17]
Barzegar JM, Siyahi MR, Barzegar-Jalai A, et al. Design and evaluation of delayed-release osmotic capsule of acetaminophen. Indian J Pharm Sci 2006; 2(2): 65-72.
[18]
Gut V, Pascal G. Delayed-release tablet with defined core geometry. US Patent 9884021B2, 2018.
[19]
Bernard CS, Michael S. Delayed-release deferiprone tablets and methods of using the same. US patent 20190125682A1, 2019.
[20]
Howard NE, Alexander BM, David S, Fiona JM, Bhardwaj V. Press coated tablet prepared for delayed release of an active ingredient. US Patent 10675247B2, 2020.
[21]
Bernard CS, Michael S. Delayed-release deferiprone tablets and methods of using the same. US patent 20200188309A1, 2020.
[22]
Karna S, Chaturvedi S, Agrawal V, Alim M. Formulation approaches for sustained release dosage forms: A review. Asian J Pharm Clin Res 2015; 8(5): 46-53.
[23]
Pundir S, Badola A, Sharma D. Sustained release matrix technology and recent advance in matrix drug delivery system: A review. Int J Drug Res Tech 2013; 3(1): 12-20.
[24]
Sahoo CK, Sahoo NK, Rao SRM, Sudhakar M, Satyanarayana K. A review on controlled porosity osmotic pump tablets and its evaluation. Bull Fac Pharm Cairo Univ 2015; 53(2): 195-205.
[http://dx.doi.org/10.1016/j.bfopcu.2015.10.004]
[25]
Swaleh MM. nisa Z, Imran Ali S, Ahmed Khan M, Rizvi M, Shehnaz S. A detailed review on oral controlled release matrix tablets. Int J Pharm Sci Rev Res 2020; 64(2): 27-38.
[http://dx.doi.org/10.47583/ijpsrr.2020.v64i02.005]
[26]
Horst GZ, Nadine P. Sustained-release bupropion, and bupropion mecamylamine tablets. US patent 7674479B2, 2010.
[27]
Michael LC, Svetlana S, Glenn CS, Feng JC. The extended-Release formulation of nevirapine. US patent 20100278918A1, 2010.
[28]
Joan CE, Montserrat GL, Inocencia ML. Extended-release venlafaxine besylate tablets. US patent 7776358B2, 2010.
[29]
Thomas F, Wolfram E. Extended-releasee tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof. US patent 7695734B2, 2010.
[30]
Kshirsagar R, Rao A, Malaviya N, Jinturkar J. Extended-release formulation of Levetiracetam. US patent 7863316B2, 2011.
[31]
Rastogi SK, Rao N. Modified release formulations of memantineoral dosage forms. US patent 8039009B2, 2011.
[32]
Kao HH, Baichwal AR, Troy MC, Lee D. An analgesically effective controlled-release tablet. US Patent 8309122B2, 2012.
[33]
Amidon GE, Ganorkar LD, Heimlich LM, Ernest J, Robert MN. Sustained-release tablet composition of pramipexole. US patent 8399016B2, 2013.
[34]
Wolfram E, Thomas F. Extended-Release tablet formulations of flibanserin and method for manufacturing the same. US patent 8545886B2, 2008.
[35]
Tian X, Haizhu F, Xiao Z, Chengdu L, Zeng Z. Anti-tumor plantmedicament sustained-release tablet of the element. US patent 8778417B2, 2014.
[36]
Baichwal AR, Philip AG, Anthony EC. Sustained release formulations of nalbuphine. US Patent 8771732B2, 2014.
[37]
Nelson A. Benzonatate modified release solid tablets and capsules. US Patent 9180104B2, 2015.
[38]
Reza F, Raday G. Antiemetic extended release solid dosage forms. US patent 9636305B2, 2017.
[39]
Hsin Yu, Perumal A, Kathala K. Methylphenidate extended-release chewable tablet. US patent 9545399B2, 2017.
[40]
Edwin RT, Eric RT, Nicholas RM, Steven FK. Extruded extendedreleaseabuse-deterrent pill. US patent 10172797B2, 2019.
[41]
Hsin Yu, Perumal A, Kathala K. Methylphenidate extended-release chewable tablet. US patent 20200188378A1, 2020.
[42]
Jonathan G, Jahan P, Ryan L, Gary N, John S. Extended-release, abuse-deterrent dosage forms. US patent 10624888B2, 2020.
[43]
Augsburger LL, Hoag SW, Eds. Pharmaceutical dosage forms-tablets. CRC Press 2016.
[http://dx.doi.org/10.1201/b15115]
[44]
Boyong L, Avinash N, Monte B. Oral extended-release composition. US patent 7476403B2, 2009.
[45]
Betterman SM, Tantry JS, Patrick LM. Extended-release topiramate capsules. US patent 8889190B2, 2014.
[46]
Betterman SM, Tantry JS, Ellsworth LM. Extended-release topiramate capsules. US patent 9555005B2, 2017.
[47]
Singh H, Ahmad S, Singh RB. Extended-release multiparticulates of ranolazine. US patent 20180344653A1, 2021.
[48]
Bellini M, Walther M, Bodmeier R. Evaluation of manufacturing process parameters causing multilayer tablets delamination. Int J Pharm 2019; 570: 118607.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118607] [PMID: 31421200]
[49]
Demiri V, Stranzinger S, Rinner P, et al. Gluing Pills Technology: A novel route to multilayer tablet manufacturing. Int J Pharm 2018; 548(1): 672-81.
[http://dx.doi.org/10.1016/j.ijpharm.2018.07.004] [PMID: 30033397]
[50]
Benjamin O, Wright CJ, David H. Tamper-resistant oral opioid agonist formulations. US Patent 7682632B2, 2010.
[51]
Caren S, Roland W, Heiko M. A two-layer extended-release tablet for the oral administration of pralnacasan, US patent 8231904B2, 2012.
[52]
Leo BK, Harry SS, Joseph RL, Frank JB. Manufacture of table having immediate release region and sustained release region. US patent 8313768B2, 2012.
[53]
Chinen HH, Sui YE, Reid ML. Gastric retentive extended-release dosage forms comprise combinations of a non-opioid analgesic and an opioid analgesic. US Patent 20120321713A1, 2012.
[54]
Admassu A, Martin K, Patel JM, Desai D, Peter T. Bilayer tablet formulations. US Patent 8535715B2, 2012.
[55]
Umit C, Ali T, Ibrahim MU, Alper T, Levent O. Dual release oral tablet compositions of dexlansoprazole. US patent 8563034B2, 2013.
[56]
Fernando GT, Glenn AM, Marcelo AR, Marcelo AC, Pastini AC, Fischbein GA. Triple combination releases multi-layered tablets. US patent 8685451B2, 2014.
[57]
Umit C, Ali T, Ibrahim MU, Alper T, Levent O. Oral tablet compositions of dexlansoprazole. US patent 8758818B2, 2014.
[58]
Kyung HK, Lee KS, Woo HS, Park JS. Pregabalin-containing, oral sustained-release triple-layer tablet. US patent 10632077B2, 2020.
[59]
Guan J, Zhou L, Nie S, Yan T, Tang X, Pan W. A novel gastric-resident osmotic pump tablet: In vitro and in vivo evaluation. Int J Pharm 2010; 383(1-2): 30-6.
[http://dx.doi.org/10.1016/j.ijpharm.2009.08.043] [PMID: 19733646]
[60]
Trenfield SJ, Basit AW. Modified drug release Current strategies and novel technologies for oral drug delivery Nanotechnology for Oral Drug Delivery. Elsevier 2020; pp. 177-97.
[http://dx.doi.org/10.1016/B978-0-12-818038-9.00006-5]
[61]
Chih YY, Jen SW, Shih WH, Yi T, Chieh WC, Cheng WC. Sustained-release oral dosage form containing dalfampridine. US patent 10172842B2, 2019.
[62]
Mondal N. The role of matrix tablet in drug delivery system. Int J Appl Pharm 2018; 10(1): 1-6.
[http://dx.doi.org/10.22159//ijap.2018v10i1.21935]
[63]
Depeursinge A, Racoceanu D, Iavindrasana J, et al. Fusing visual and clinical information for lung tissue classification in high-resolution computed tomography. Artif Intell Med 2010; 50(1): 13-21.
[http://dx.doi.org/10.1016/j.artmed.2010.04.006] [PMID: 20547044]
[64]
Wendell GM, Santos JM, Singh EC, Kennie UD. Method for producing extended-release potassium citrate wax matrix tablet. US patent 20150231267A1, 2021.
[65]
Vaka SRK, Shelke NB, Desai D, Phuapradit W, Shah NH. Extended-release compositions comprising pyridostigmine. US patent 20190374473A1, 2021.
[66]
Hemchand P, Doye Avinash R, Tukaram MS, Mahavir B. Recent advances in different aspects of tablet coating. Available from: https://www.semanticscholar.org/paper/RECENT-ADVANCES-IN-DIFFERENT-ASPECTS-OF-TABLET-Hemchand-DoyeAvinash/b92bab6abe91268be23f25d894e630233805c254
[67]
Chen X, Wen H, Park K. Challenges and new technologies of oral controlled release. Oral controlled release formulation design and drug delivery. Theory Pract 2010; 16: 257-77.
[68]
Ando M, Ito R, Ozeki Y, Nakayama Y, Nabeshima T. Evaluation of a novel sugar coating method for moisture protective tablets. Int J Pharm 2007; 336(2): 319-28.
[http://dx.doi.org/10.1016/j.ijpharm.2006.12.015] [PMID: 17258875]
[69]
Ketterhagen W, Aliseda A. Modeling tablet film-coating processes.In predictive modeling of pharmaceutical unit operations. Elsevier Inc. 2017; pp. 273-316.
[70]
Zaid AN. comprehensive review on pharmaceutical film coating Past, present, and future. In Drug Design, Development and Therapy. Dove Medical Press Ltd 2020; p. 14: pp. 4613-23.Dove Medical Press Ltd 2020;. 14.
[71]
Maderuelo C, Lanao JM, Zarzuelo A. Enteric coating of oral solid dosage forms as a tool to improve drug bioavailability. Eur J Pharm Sci 2019; 138: 105019.
[http://dx.doi.org/10.1016/j.ejps.2019.105019] [PMID: 31374253]
[72]
Arora R, Rathore KS, Bharakatiya M. An overview on tablet coating. As J Pharm. Res Develop 2019; 7(4): 89-92.
[http://dx.doi.org/10.22270/ajprd.v7i4.547]
[73]
Thakral S, Thakral NK, Majumdar DK. Eudragit®: A technology evaluation. Expert Opin Drug Deliv 2013; 10(1): 131-49.
[http://dx.doi.org/10.1517/17425247.2013.736962] [PMID: 23102011]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy